Myeloid differentiation and maturation of SCF+IL-3+IL-11 expanded AC133+/CD34+ cells selected from high-risk breast cancer patients
Language English Country Slovakia Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
10985471
Knihovny.cz E-resources
- MeSH
- AC133 Antigen MeSH
- Antigens, CD34 biosynthesis blood immunology MeSH
- Antigens, CD MeSH
- Cyclophosphamide adverse effects MeSH
- Adult MeSH
- Etoposide administration & dosage MeSH
- Granulocyte Colony-Stimulating Factor administration & dosage MeSH
- Hematopoietic Cell Growth Factors pharmacology MeSH
- Glycoproteins biosynthesis blood immunology MeSH
- Hematopoietic Stem Cells cytology drug effects immunology MeSH
- Interleukin-11 pharmacology MeSH
- Interleukin-3 pharmacology MeSH
- Leukapheresis MeSH
- Middle Aged MeSH
- Humans MeSH
- Hematopoietic Stem Cell Mobilization MeSH
- Breast Neoplasms blood drug therapy immunology MeSH
- Peptides blood immunology MeSH
- Antineoplastic Combined Chemotherapy Protocols therapeutic use MeSH
- Recombinant Proteins pharmacology MeSH
- Stem Cell Factor pharmacology MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- AC133 Antigen MeSH
- Antigens, CD34 MeSH
- Antigens, CD MeSH
- Cyclophosphamide MeSH
- Etoposide MeSH
- Granulocyte Colony-Stimulating Factor MeSH
- Hematopoietic Cell Growth Factors MeSH
- Glycoproteins MeSH
- Interleukin-11 MeSH
- Interleukin-3 MeSH
- Peptides MeSH
- PROM1 protein, human MeSH Browser
- Recombinant Proteins MeSH
- Stem Cell Factor MeSH
The AC133 antigen is selectively expressed on subset of CD 34+ cells isolated from leukapheresis products from high risk breast cancer patients receiving chemotherapy plus G-CSF. MiniMACS AC133+ isolated cells contained a mean of 85% (80-90) AC133+ cells. Enriched AC133+ cells coexpressed 80% CD34+, 6.6% CD33+ and 2% CD15+. Separated AC133+ cells contained 600 GFU-GM/10(4) cells and 70 BFU-E/10(4) cells. Flow-cytometric analysis indicated that AC133+ cells were isolated from cells population with low granularity (SS), while CD33+ a CD15+ cells had a high granularity. After a seven-day ex vivo expansion in the presence of SCF + IL-3 + IL11, the expansion of cells increased 19.4 times. The mean percentage of blasts decreased from 100% at the start of culture to 81% on day 3 and 30% on day 7. Promyelocytes were slow to appear with 10% present on day 3, but thereafter increased to 33% on day 7. The appearance of myelocytes and metamyelocytes lagged 3 days behind promyelocytes and continued to increase during culture to become the predominant (30%) cell type on day 7. Very few neutrophils (2%) were observed in any of the cultures on day 7. Monocytes or macrophages were not detected on day 7. By day 7 megakaryocytes were present at low levels (10%). The mean value of CFU-GM in the culture after day 7 of ex vivo expansion in the presence of SCF+IL-3+IL-11 had increased 45-fold, BFU-E 5-fold. After 7 days of expansion with IL-3+SCF+IL-11 cells expressed a mean of 12% CD34+, 8% AC133+, 59% CD33+ and 30% CD15+. The aim of this experiment was to determine whether ex vivo culture of peripheral blood AC133+ cells could generate sufficient numbers of progenitors to potentially abrogate cytopenia after transplantation and passive purging of tumor cells.
